Should You Continue to Hold ACHC Stock at an 18.17X P/E Valuation?
Zacks reports that Acadia Healthcare's premium valuation (18.17x P/E) faces a key test, with facility growth and stronger EBITDA guidance balanced against rising costs and weaker returns. The article weighs these competing factors for ACHC's outlook.
Why it matters — ACHC watchers would care because the piece highlights the tension between the company's growth and earnings guidance and the cost pressures and weaker returns that could affect its premium valuation.